Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2014
Q3
$2.59M Sell
39,900
-7,300
-15% -$462K ﹤0.01% 2658
2014
Q2
$2.93M Buy
47,200
+4,800
+11% +$286K ﹤0.01% 2500
2014
Q1
$2.5M Sell
42,400
-127,800
-75% -$7.13M ﹤0.01% 2560
2013
Q4
$8.68M Buy
170,200
+129,800
+321% +$6.5M 0.01% 1373
2013
Q3
$2.03M Buy
40,400
+11,700
+41% +$613K ﹤0.01% 2565
2013
Q2
$1.41M Buy
+28,700
New +$1.56M ﹤0.01% 2929

Other funds holding LLY

UBS's LLY Position: Q3 2014 in Review

UBS increased its Eli Lilly (LLY) stake by 5.7% in Q3 2014, buying an estimated $2.43M and bringing the position to 707,528 shares worth $45.9M. The position accounts for 0.03% of the portfolio, ranked #545.

UBS first reported a position in LLY in Q2 2013 and has held it in 6 quarters since. The position peaked at $46M in Q3 2013. 1,041 funds tracked by Wall St. Rank hold LLY as of Q3 2014.

  • UBS held 707,528 shares of Eli Lilly worth $45.9M as of Q3 2014.
  • UBS bought 38,330 Eli Lilly shares in Q3 2014, an estimated $2.43M.
  • Eli Lilly made up 0.03% of UBS's portfolio in Q3 2014, its #545 holding.
  • UBS first reported a position in Eli Lilly in Q2 2013 and has held it in 6 quarters since.
  • UBS's Eli Lilly position peaked at $46M in Q3 2013.
  • 1,041 funds tracked by Wall St. Rank held Eli Lilly as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.